Company intelligence / Profile preview

Honeybrains

Ownership: Private
Development stage: Phase 2

Overview

Honeybrains Biotech is conducting Phase 2 clinical trials for HB-1, a fixed dose combination of 96 mg telmisartan and 288 mg verapamil, targeting Panic Disorder. The trial is evaluating safety and efficacy in approximately 80 patients.

Therapeutic areas: Psychiatry
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

HB-1

Phase 2

Indications: Panic disorder

Beyond the preview

Go deeper on Honeybrains.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Honeybrains.

Explore the full profile